NeuroOne Medical Technologies Corp Regains Nasdaq Compliance – Key Update for Investors

NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) has provided a significant regulatory update that could have material implications for shareholders and potential investors. The company recently announced that it has successfully regained compliance with the Nasdaq Capital Market’s minimum bid price requirement, a key standard for maintaining its public listing.

Key Points from the Report

• Previous Non-Compliance Notice: On May 6, 2025, NeuroOne received a deficiency letter from the Nasdaq Stock Market LLC’s Listing Qualifications Department. The notice stated that, for 30 consecutive business days, the closing bid price of the company’s common stock was below \$1.00 per share, which violated Nasdaq Listing Rule 5550(a)(2). This rule requires listed companies to maintain a minimum closing bid price of \$1.00 per share to remain eligible for continued listing on the Nasdaq Capital Market.
• Regaining Compliance: On April 30, 2026, Nasdaq notified NeuroOne that the company had cured this deficiency. The closing bid price of its common stock had reached \$1.00 or greater for at least 10 consecutive business days, as required to regain compliance. As a result, Nasdaq has closed the matter, and the company’s listing is no longer at risk due to this issue.

What Shareholders Need to Know & Potential Price Sensitivity

• Risk of Delisting Averted: The risk of being delisted from the Nasdaq Capital Market, which could have had a highly negative impact on share liquidity, market perception, and overall shareholder value, has now been removed. The company’s shares will continue trading under the symbol NMTC on the Nasdaq exchange.
• Share Price Stability: Regaining compliance eliminates a major overhang that could have pressured the stock price due to concerns about forced delisting or a potential reverse stock split. Investors who may have been waiting on the sidelines due to uncertainty around the listing status may now view the company as a more stable investment opportunity.
• No Reverse Split: The company was able to resolve the deficiency through natural price appreciation rather than implementing a reverse stock split, which can sometimes be interpreted as a negative signal.
• Continued Compliance Required: While this episode is resolved, the company and its shareholders should remain aware that ongoing compliance with Nasdaq’s listing standards is critical for maintaining the benefits of a national exchange listing.
• Corporate Details: NeuroOne Medical Technologies Corp is incorporated in Delaware, with its principal executive office located at 7599 Anagram Dr, Eden Prairie, MN 55344. The company’s EIN is 27-0863354, and the Nasdaq trading symbol is NMTC.

Summary Table

Other Regulatory Details

• No written communications under Rule 425, no soliciting material under Rule 14a-12, and no pre-commencement communications under Rule 14d-2(b) or 13e-4(c) were filed in this 8-K.
• The company is not currently classified as an “emerging growth company.”

Potential Share Price Impact

This announcement may have a positive impact on the share price of NeuroOne Medical Technologies Corp as it removes a significant regulatory risk and may improve investor confidence in the company’s prospects. The restoration of Nasdaq compliance can attract new investors and reassure current shareholders of the stability of their investment.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence and consult with financial advisors before making investment decisions. The information contained herein is based on public filings and may be subject to change.

View NEUROONE MEDICAL TECHNOLOGIES Corp Historical chart here